Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

Documenti analoghi

• Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
  di: Patrick Born, et al.
  Pubblicazione: (2025)
• Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma
  di: Nil Albiol, et al.
  Pubblicazione: (2026)
• Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD‐1 blockade
  di: Thomas M. Kuczmarski, et al.
  Pubblicazione: (2025)
• High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
  di: Andrea Manubens, et al.
  Pubblicazione: (2025)
• Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study
  di: Axel André, et al.
  Pubblicazione: (2024)